 Connection
Daniel LaBarbera to Neoplasms
This is a "connection" page, showing publications Daniel LaBarbera has written about Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.462 |
|
|
|
-
Clune S, Awolade P, Esquer H, Zhou Q, LaBarbera DV. CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential. J Exp Clin Cancer Res. 2025 May 30; 44(1):167.
Score: 0.313
-
Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer. Biomed Pharmacother. 2024 Jan; 170:116037.
Score: 0.284
-
Kellett T, Noor R, Zhou Q, Esquer H, Sala R, Stojanovic P, Rudolph J, Luger K, LaBarbera DV. HTS discovery of PARP1-HPF1 complex inhibitors in cancer. SLAS Discov. 2023 12; 28(8):394-401.
Score: 0.280
-
Esquer H, Zhou Q, Nemkov T, Abraham AD, Rinaldetti S, Chen YC, Zhang X, Orman MV, D'Alessandro A, Ferrer M, Messersmith WA, LaBarbera DV. Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. Oncogene. 2021 04; 40(16):2884-2897.
Score: 0.234
-
Esquer H, Zhou Q, Abraham AD, LaBarbera DV. Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discov. 2020 08; 25(7):734-743.
Score: 0.222
-
LaBarbera DV, Reid BG, Yoo BH. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Discov. 2012 Sep; 7(9):819-30.
Score: 0.128
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|